Supporting the LCA community
We see a cure for blindness
What is Leber Congenital Amaurosis (LCA)?
LCA is a rare inherited retinal disease characterized by severe vision loss at birth. While some children are born with little or no vision, others may have significant vision loss in the first few years of life, stable vision for a period of time, and then eventually complete vision loss as the retina deteriorates into total blindness.
What We Do
Founded in 2014 as Sofia Sees Hope, Hope in Focus is a nonprofit 501(c)3 patient advocacy organization dedicated to generating awareness, raising funds for research, and providing support, education and outreach to the LCA and rare inherited retinal disease community.
Thank you to these organizations
for their ongoing commitment to Hope in Focus.
Let’s Get Social!
[fts_twitter twitter_name=SofiaSeesHope tweets_count=4 cover_photo=no stats_bar=no show_retweets=no show_replies=no]
We are happy to see that the 12-month trial data for Atsena Therapeutics' LCA1 GUCY2D gene therapy clinical trial continues to show positive results. Read more in the press release for updates on their progress below. ![]()
![]()
#LCA1 #LCA #clinicaltrial #HopeInFocus ![]()
![]()
Image Description: Little boy with white cane linking to Atsena Therapeutics website.
atsenatx.com
Atsena Therapeutics Announces Positive 12-month Safety and Efficacy Data from Ongoing Phase I/II Clinical Trial of ATSN-101 in Patients with Leber Congenital Amaurosis Caused by ...